DFFN RSI Chart
Last 7 days
11.9%
Last 30 days
20.1%
Last 90 days
-14.5%
Trailing 12 Months
-51.6%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 7.8M | 0 | 0 | 0 |
2023 | 0 | 0 | 0 | 7.1M |
2022 | 0 | 0 | 0 | 0 |
2021 | 0 | 0 | 0 | 0 |
2020 | 0 | 0 | 0 | 0 |
2019 | 0 | 0 | 0 | 0 |
2018 | 0 | 0 | 0 | 0 |
2017 | 0 | 0 | 2.9M | 0 |
2014 | 1.5M | 2.0M | 2.4M | 0 |
2013 | 1.6M | 1.5M | 1.3M | 1.1M |
2012 | 3.7M | 3.6M | 2.8M | 1.8M |
2011 | 0 | 2.2M | 2.8M | 3.3M |
2010 | 0 | 0 | 0 | 1.7M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Jun 30, 2023 | lanchoney diana m | back to issuer | - | - | -85.00 | - |
Jun 30, 2023 | lanchoney diana m | acquired | - | - | 232 | - |
May 31, 2023 | hollingsworth jane h | back to issuer | - | - | -68.00 | - |
May 31, 2023 | hollingsworth jane h | acquired | - | - | 183 | - |
Mar 31, 2023 | lanchoney diana m | back to issuer | - | - | -85.00 | - |
Mar 31, 2023 | lanchoney diana m | acquired | - | - | 232 | - |
Feb 28, 2023 | hollingsworth jane h | back to issuer | - | - | -68.00 | - |
Feb 28, 2023 | hollingsworth jane h | acquired | - | - | 183 | - |
Jan 31, 2023 | cobuzzi robert joseph jr. | back to issuer | - | - | -121 | president & ceo |
Jan 31, 2023 | cobuzzi robert joseph jr. | acquired | - | - | 327 | president & ceo |
Which funds bought or sold DFFN recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Jul 27, 2023 | TimeScale Financial, Inc. | unchanged | - | -7.00 | 30.00 | -% |
Nov 01, 2022 | Strategic Asset Management, LLC | unchanged | - | - | - | -% |
Aug 15, 2022 | Frontier Wealth Management LLC | sold off | -100 | -7,000 | - | -% |
Dec 08, 2021 | Homrich & Berg | unchanged | - | -2,000 | 5,000 | -% |
Jul 28, 2021 | Hoover Financial Advisors, Inc. | new | - | 3,000 | 3,000 | -% |
Unveiling Diffusion Pharmaceuticals Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Diffusion Pharmaceuticals Inc. News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q1 | 2022Q4 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Revenue | -5.8% | 2,347,250 | 2,490,578 | 1,526,482 | 1,407,868 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses | -1.7% | 4,942,188 | 5,029,405 | 4,201,611 | 2,834,187 | 938,823 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
S&GA Expenses | -100.0% | - | 1,133,109 | 2,410,124 | 2,957,691 | -1,071,093 | - | - | - | - | - | - | - | - | - | - | - | - | 1,290,371 | 1,068,452 | 1,200,728 | 1,419,087 |
R&D Expenses | -30.7% | 2,814,258 | 4,060,794 | 1,791,487 | 1,308,589 | -1,573,920 | - | - | - | - | - | - | - | - | - | - | - | - | 1,743,494 | 1,518,381 | 1,699,845 | 1,365,449 |
EBITDA Margin | 8.1% | -2.96 | -3.22 | -7.94 | -7.94 | -7.94 | -7.83 | -8.46 | -8.45 | -8.44 | -8.64 | - | - | - | - | - | - | - | - | - | - | - |
Interest Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Income Taxes | - | - | - | - | - | 421,947 | - | - | - | - | - | - | - | - | - | - | - | - | -225,960 | -108,904 | -150,352 | 45,136 |
Earnings Before Taxes | - | - | - | - | - | -4,075,964 | - | - | - | - | - | - | - | - | - | - | - | - | -3,030,052 | -2,604,302 | -2,898,161 | -5,525,802 |
EBT Margin | 8.1% | -2.96 | -3.22 | -7.94 | -7.94 | -7.94 | -7.84 | -8.48 | -8.48 | -8.48 | -8.68 | - | - | - | - | - | - | - | - | - | - | - |
Net Income | -144.4% | -2,514,335 | -1,028,956 | 2,150,362 | -4,092,384 | 1,134,659 | - | - | - | - | - | - | - | - | - | - | - | - | -2,804,092 | -2,495,398 | -2,747,809 | -5,570,938 |
Net Income Margin | 49.5% | -0.25 | -0.49 | -0.46 | -2.77 | -2.92 | -4.52 | -8.42 | -8.28 | -8.32 | -8.53 | - | - | - | - | - | - | - | - | - | - | - |
Free Cashflow | 43.9% | -1,423,674 | -2,538,454 | 2,693,546 | -4,977,339 | -701,749 | 6,847,559 | -4,016,413 | -4,739,032 | -3,034,706 | -2,981,747 | - | - | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -19.8% | 8.00 | 10.00 | 12.00 | 3.00 | 4.00 | 4.00 | 26.00 | 29.00 | 34.00 | 38.00 | 41.00 | 53.00 | 56.00 | 28.00 | 32.00 | 36.00 | 21.00 | 24.00 | 16.00 | 19.00 | 16.00 |
Current Assets | -20.1% | 8.00 | 10.00 | 12.00 | - | 18.00 | 4.00 | 26.00 | 29.00 | 34.00 | 38.00 | 41.00 | 44.00 | 47.00 | 19.00 | 23.00 | 27.00 | 12.00 | 15.00 | 7.00 | 9.00 | 6.00 |
Cash Equivalents | -18.3% | 6.00 | 8.00 | 10.00 | 15.00 | 15.00 | 4.00 | 5.00 | 6.00 | 10.00 | 7.00 | 40.00 | 43.00 | 47.00 | 19.00 | 22.00 | 26.00 | 11.00 | 14.00 | 6.00 | 8.00 | 5.00 |
Net PPE | - | - | - | - | - | - | - | - | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Liabilities | 2.5% | 3.00 | 3.00 | 2.00 | 1.00 | 2.00 | 13.00 | - | - | - | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 4.00 | 3.00 | 3.00 | 3.00 |
Current Liabilities | - | - | - | - | - | - | - | 2.00 | 3.00 | 3.00 | 3.00 | 3.00 | 2.00 | 2.00 | 2.00 | 3.00 | 2.00 | 1.00 | 2.00 | 1.00 | 1.00 | 1.00 |
Shareholder's Equity | -27.7% | 5.00 | 7.00 | 10.00 | 14.00 | 16.00 | 20.00 | 24.00 | 27.00 | 31.00 | 35.00 | 38.00 | 50.00 | 54.00 | 25.00 | 29.00 | 33.00 | 18.00 | 20.00 | 14.00 | 16.00 | 13.00 |
Retained Earnings | -4.7% | -56.96 | -54.40 | -52.08 | -54.23 | -52.80 | -52.27 | -141 | -138 | -134 | -130 | -126 | -114 | -110 | -105 | -101 | -97.41 | -94.28 | -91.72 | -87.97 | -85.17 | -82.67 |
Additional Paid-In Capital | 0.8% | 62.00 | 62.00 | 62.00 | 166 | 166 | 19.00 | 166 | 165 | 165 | 165 | 165 | 164 | 164 | 131 | 131 | 130 | 112 | 112 | 101 | 101 | 96.00 |
Shares Outstanding | 8.7% | 6.00 | 6.00 | 6.00 | 2.00 | 2.00 | 1.00 | 1.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | - | - | - | - | - | - | - | - | - |
Float | -100.0% | - | 7.00 | - | - | - | - | - | 14.00 | - | - | - | 74.00 | - | - | - | 62.00 | - | - | - | 13.00 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | 43.9% | -1,423 | -2,538 | 2,703 | -2,646 | -4,968 | -692 | 6,857 | -4,007 | -4,729 | -3,025 | -2,972 | -3,327 | -5,176 | -3,394 | -3,510 | -3,143 | -3,504 | -2,438 | -2,152 | -2,610 | -2,657 |
Share Based Compensation | 32.3% | 218 | 165 | 61.00 | 61.00 | 121 | 81.00 | -303 | 278 | 278 | 254 | 164 | 297 | 181 | 152 | 279 | 113 | 191 | 130 | 145 | 149 | 91.00 |
Cashflow From Investing | - | - | - | - | 3,000 | 9,500 | 7,000 | 3,380 | 101 | -22,716 | 4.00 | - | - | - | - | - | - | - | - | - | - | - |
Cashflow From Financing | 100.0% | - | -93.37 | 11,242 | - | - | - | -5.00 | - | 5.00 | - | - | - | 33,296 | - | -141 | 17,877 | 155 | 10,476 | -80.21 | - | - |
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Grant revenue | $ 2,347,250 | $ 1,407,868 |
Operating expenses: | ||
Research and development | 2,814,258 | 1,833,274 |
General and administrative | 2,127,930 | 1,000,913 |
Total operating expenses | 4,942,188 | 2,834,187 |
Loss from operations | (2,594,938) | (1,426,319) |
Other income (expense): | ||
Other income (expense) | (30) | 856,579 |
Interest income | 80,633 | 35,404 |
Total other income, net | 80,603 | 891,983 |
Net loss | $ (2,514,335) | $ (534,336) |
Per share information: | ||
Net loss per share of common stock, basic and diluted (in dollars per share) | $ (0.41) | $ (1.03) |
Weighted average shares outstanding, basic and diluted (in shares) | 6,170,501 | 518,140 |
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 6,369,172 | $ 7,792,846 |
Deferred offering costs | 247,671 | 0 |
Prepaid expenses | 1,348,679 | 1,256,501 |
Grant receivable | 0 | 915,404 |
Total current assets | 7,965,522 | 9,964,751 |
Other assets | 31,926 | 7,770 |
Total assets | 7,997,448 | 9,972,521 |
Current liabilities: | ||
Accounts payable | 679,739 | 662,471 |
Deferred grant revenue | 572,475 | 0 |
Accrued expenses and other current liabilities | 1,408,856 | 1,933,276 |
Total liabilities | 2,661,070 | 2,595,747 |
Commitments and Contingencies | ||
Stockholders’ Equity: | ||
Series A preferred stock $0.001 par value; 30,000,000 authorized at March 31, 2024 and December 31, 2023, 0 shares issued and outstanding at March 31, 2024 and December 31, 2023 | 0 | 0 |
Common stock, $0.001 par value: 1,000,000,000 shares authorized: 6,170,479 and 5,674,520 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 6,170 | 5,674 |
Additional paid-in capital | 62,285,332 | 61,811,889 |
Accumulated deficit | (56,955,124) | (54,440,789) |
Total stockholders' equity | 5,336,378 | 7,376,774 |
Total liabilities and stockholders' equity | $ 7,997,448 | $ 9,972,521 |